简介:摘要程序性细胞死亡蛋白1(PD-1)的单克隆抗体可以阻断PD-1与其配体之间的相互作用,恢复T细胞的抗肿瘤作用。PD-1抑制剂已被广泛批准用于治疗各种恶性肿瘤。有大量文献报道了信迪利单抗有令人满意的抗肿瘤作用,同时也报道出一些相关不良反应。由PD-1抑制剂引起的急性自身免疫性胰岛素依赖型糖尿病在儿童中非常罕见。现报道广东药科大学附属第一医院2021年11月收治的1例应用PD-1抗体后出现高血糖症儿童。
简介:ObjectiveChronictinnitusisahighlyprevalentconditionandhasbeenhypothesizedtoresultfromaninnatedisturbanceincentralnervousserotonergictransmission.Giventhefrequentcomorbiditywithmajordepressionandanxiety,wearguethatcandidategenesforthesedisordersarelikelytooverlap.Thepresentstudyaddressesthegeneencodingforthe5-HT1Areceptorasaputativeriskfactorfortinnitus.MethodsIn88subjectswithadiagnosisofchronicsubjectivetinnituswhounderwentadetailedneurootologicalexamination,theentire5-HT1AgenewasamplifiedusingoverlappingPCRproducts.Ampliconswerecustomsequencedbidirectionallyandwerescreenedforvariantsinmultiplealignmentsagainstthehumangenomereference.ResultsWeidentifiedasynonymousC>Texchangeatresidue184(Pro)in7/88subjects,butdetectednomissensevariantsinthepopulationunderstudy.Specifically,thefollowingresidueswerefullyconserved:16(Pro),22(Gly),28(Ile),98(Val),220(Arg),267(Val),273(Gly),and418(Asn).DiscussionThepresentdatacountagainstthecausationofchronictinnitusbyachangeinthe5-HT1Areceptor'saminoacidsequence.However,theallelefrequencyforthe184Prominorallele(0.04)reachedtwicethefrequencyreportedincontrolcohortsfromthesameethnicity.Additionalinvestigationsareinvitedtoclarifytheroleofthe5-HT1Apolymorphisminlargersamples,andtocontrolforcomorbidaffectivedisorders.
简介:摘要IgA肾病(IgA nephropathy,IgAN)是儿童及青少年最常见的原发性肾小球肾炎,是慢性肾脏病和终末期肾病的主要原因。目前IgAN发病机制尚未完全清楚,可能与多重免疫打击有关。即半乳糖缺陷型IgA1(galactose-deficient IgA1,Gd-IgA1)形成(第一重打击);抗Gd-IgA1的自身抗体合成(第二重打击); Gd-IgA1与自身抗体结合形成循环免疫复合物(第三重打击);这些含有Gd-IgA1的循环免疫复合物在肾小球系膜中沉积,引发肾脏损害(第四重打击)。Gd-IgA1是IgAN发生发展始发及驱动的关键因素,核心1β1,3-半乳糖基转移酶(core 1,β1,3-galactosyltransferase,C1GALT1)是IgA1 O-糖基化过程中的关键酶,其表达减少和(或)活性下降与Gd-IgA1的产生密切相关。该综述阐述了C1GALT1在IgAN发病、治疗及预后中的作用。
简介:AbstractThe COVID-19 pandemic is still raging across the world. Everyday thousands of infected people lost their lives. What is worse, there is no specific medicine and we do not know when the end of the pandemic will come. The nearest global pandemic is the 1918 influenza, which caused about 50 million deaths and partly terminate the World War I. We believe that no matter the virus H1N1 for the 1918 influenza or 2019-nCoV for COVID-19, they are essentially the same and the final cause of death is sepsis. The definition and diagnostic/management criteria of sepsis have been modified several times but the mortality rate has not been improved until date. Over decades, researchers focus either on the immunosuppression or on the excessive inflammatory response following trauma or body exposure to harmful stimuli. But the immune response is very complex with various regulating factors involved in, such as neurotransmitter, endocrine hormone, etc. Sepsis is not a kind of disease, instead a misbalance of the body following infection, trauma or other harmful stimulation. Therefore we should re-think sepsis comprehensively with the concept of systemic biology, i.e. inflammationomics.
简介:目的探讨甲型H1N1流感患者心脏损害的特点。方法回顾性研究分析2009年7月至2010年1月期间确诊为甲型H1N1流感患者172例的临床资料,所有患者根据病情分为轻症组,重症组,危重症组,并收集非甲型H1N1流感患者21例作为对照。大部分患者接受分子生物学检测磷酸肌酸激酶,磷酸肌酸激酶同工酶,高敏C反应蛋白,并接受胸部X线摄片检查,计算心胸比。结果甲型H1N1流感多发生于青壮年患者,轻症患者较重症患者更年轻(P<0.05)。在危重症患者中,磷酸肌酸激酶,磷酸肌酸激酶同工酶,高敏C反应蛋白和心胸比均较其他组高(P<0.05或P<0.01)。1例死于心肌损害。结论与既往研究相符,2009甲型H1N1流感可以导致心肌损害,特别是在危重症患者中心肌损害较显著,从而将导致心脏扩大等损害,导致死亡率升高。
简介:
简介:【摘要】目的:探讨接种甲型 H1NI流感疫苗的应用效果和价值。方法:选取 120例 2015年 8月— 2016年 8月间在我院接种甲型 H1NI疫苗人员为接种组,按照年龄、性别、疾病匹配选取未接种甲型 H1NI流感疫苗者 120例为对照组。调查接种组在接种疫苗后 90d内的甲型 H1NI流感及其他流感样疾病发生的情况,在疫苗接种后 48h内的不良反应发生情况。结果:接种组 90d内甲型 H1N1流感发病率为 0%,未有就诊记录。对照组甲型 H1N1流感发病率及就诊率为 7.3%,两组差异有统计学意义( P< 0.05);接种组在疫苗接种后 90d内的流感保护率为 100%,就诊率减少 100%。接种组的其他流感疾病发生率为 15%,就诊率为 8.3%,对照组为 22.7%和 16.3%,差异有统计学意义( P< 0.05);接种组在 90d内其他流感疾病保护率为 33.9%,减少就诊 49.4%,共出现 8例不良反应,占比 6.7%,症状较轻。结论:接种甲型 H1N1疫苗可见明显的流感预防效果,具备安全性。